SE446265B - 2-metyl-1,4-dihydropyridinforeningar - Google Patents

2-metyl-1,4-dihydropyridinforeningar

Info

Publication number
SE446265B
SE446265B SE7908367A SE7908367A SE446265B SE 446265 B SE446265 B SE 446265B SE 7908367 A SE7908367 A SE 7908367A SE 7908367 A SE7908367 A SE 7908367A SE 446265 B SE446265 B SE 446265B
Authority
SE
Sweden
Prior art keywords
methyl
dihydropyridine
carboxylic acid
compound
ester
Prior art date
Application number
SE7908367A
Other languages
English (en)
Swedish (sv)
Other versions
SE7908367L (sv
Inventor
Y Sato
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of SE7908367L publication Critical patent/SE7908367L/xx
Publication of SE446265B publication Critical patent/SE446265B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/56—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups bound to carbon atoms of six-membered aromatic rings and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
SE7908367A 1978-10-10 1979-10-09 2-metyl-1,4-dihydropyridinforeningar SE446265B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB7839978 1978-10-10

Publications (2)

Publication Number Publication Date
SE7908367L SE7908367L (sv) 1980-04-11
SE446265B true SE446265B (sv) 1986-08-25

Family

ID=10500226

Family Applications (2)

Application Number Title Priority Date Filing Date
SE7908367A SE446265B (sv) 1978-10-10 1979-10-09 2-metyl-1,4-dihydropyridinforeningar
SE8400689A SE446096B (sv) 1978-10-10 1984-02-09 Mellanprodukter till anvendning for framstellning av farmakologiskt aktiva 2-metyl-1,4-dihydropyridinforeningar

Family Applications After (1)

Application Number Title Priority Date Filing Date
SE8400689A SE446096B (sv) 1978-10-10 1984-02-09 Mellanprodukter till anvendning for framstellning av farmakologiskt aktiva 2-metyl-1,4-dihydropyridinforeningar

Country Status (10)

Country Link
JP (2) JPS5562065A (hu)
BE (1) BE879263A (hu)
CA (1) CA1117117A (hu)
CH (1) CH642353A5 (hu)
DE (1) DE2940833A1 (hu)
FR (1) FR2438654A1 (hu)
GB (1) GB2036722B (hu)
IT (1) IT1125469B (hu)
NL (1) NL7907482A (hu)
SE (2) SE446265B (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7910521L (sv) * 1979-12-20 1981-06-21 Haessle Ab Nya 2-metyl-6-substituerade-4-(2,3-disubstituerad fenyl)-1,4-dihydropyridin-3,5-diestrar med hypotesiva egenskaper, samt forfarande for deras framstellning, och farmaceutiska beredningar innehallande desamma
JPS57175164A (en) * 1981-04-18 1982-10-28 Banyu Pharmaceut Co Ltd 1,4-dihydropyridine derivative and its preparation
DE3269219D1 (en) * 1981-11-17 1986-03-27 Fisons Plc Dihydropyridines, methods for their production and their formulation and use as pharmaceuticals
ZA83959B (en) * 1982-03-10 1984-09-26 Sandoz Ltd 1,4-dihydropyridine derivatives,their preparation and pharmaceutical compositions containing them
CH655110A5 (de) * 1982-09-03 1986-03-27 Otsuka Pharma Co Ltd Carbostyrilderivate, verfahren zu deren herstellung und arzneimittel, welche diese enthalten.
DE3312216A1 (de) * 1983-04-05 1984-10-11 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von symmetrischen 1,4-dihydropyridincarbonsaeureestern
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固形製剤
GB8412208D0 (en) * 1984-05-12 1984-06-20 Pfizer Ltd Quinolone inotropic agents
GB8431119D0 (en) * 1984-12-10 1985-01-16 Fujisawa Pharmaceutical Co Anti-arteriosclerotic composition
GB8602518D0 (en) * 1986-02-01 1986-03-05 Wyeth John & Brother Ltd 1 4-dihydropyridines
JPS63115890A (ja) * 1986-10-31 1988-05-20 Nippon Shinyaku Co Ltd ２位置換１，４−ジヒドロピリジン誘導体
US5114946A (en) * 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
ES2043719T3 (es) * 1987-06-12 1994-01-01 American Cyanamid Co Administracion de farmacos por via percutanea.
US5045553A (en) * 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
ATE105476T1 (de) * 1987-12-29 1994-05-15 Fujisawa Pharmaceutical Co Dihydropyridin-verbindung zur verbesserung der adernausdehnung und hemmung der herzhypertrophie.
DE3888144T2 (de) * 1987-12-29 1994-06-23 Fujisawa Pharmaceutical Co Gehirn-Neuron schützendes Mittel, enthaltend eine Dihydropyridin-Verbindung.
JP2007230869A (ja) * 2004-04-05 2007-09-13 Takeda Chem Ind Ltd アルドステロン受容体拮抗剤
CN101987833B (zh) * 2009-08-04 2014-07-30 北京利乐生制药科技有限公司 尼伐地平晶型及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1552911A (en) * 1975-07-02 1979-09-19 Fujisawa Pharmaceutical Co 1,4 dihydropyridine derivatives and the preparation thereof
GB1591089A (en) * 1976-12-17 1981-06-10 Fujisawa Pharmaceutical Co 1,4-dihydropyridine derivatives and process for preparation thereof
DE2658183A1 (de) * 1976-12-22 1978-07-06 Bayer Ag In 2-position substituierte 1,4- dihydropyridin-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel

Also Published As

Publication number Publication date
DE2940833A1 (de) 1980-04-30
JPS6125711B2 (hu) 1986-06-17
FR2438654A1 (fr) 1980-05-09
GB2036722A (en) 1980-07-02
FR2438654B1 (hu) 1983-01-14
SE7908367L (sv) 1980-04-11
SE8400689L (sv) 1984-02-09
IT7926362A0 (it) 1979-10-09
JPS61118366A (ja) 1986-06-05
BE879263A (fr) 1980-04-08
NL7907482A (nl) 1980-04-14
JPS6143343B2 (hu) 1986-09-26
CA1117117A (en) 1982-01-26
DE2940833C2 (hu) 1989-01-26
IT1125469B (it) 1986-05-14
SE446096B (sv) 1986-08-11
GB2036722B (en) 1982-12-01
SE8400689D0 (sv) 1984-02-09
CH642353A5 (de) 1984-04-13
JPS5562065A (en) 1980-05-10

Similar Documents

Publication Publication Date Title
SE446265B (sv) 2-metyl-1,4-dihydropyridinforeningar
US5654309A (en) Pyridopyrimidine derivatives, their production and use
US5411970A (en) Method of inhibiting lentivirus
HU207314B (en) Process for producing 6-benzoxazinyl- and 6-benzthiazinyl-2,3,4,5-tetrahydropyridazin-3-ones and pharmaceutical compositions containing them
US4996204A (en) Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
JPS635035B2 (hu)
El-Hamouly et al. Synthesis of new 4-aryl-isoxazolo [5, 4-d] pyrimidin-6-one (thione) and 4-aryl-pyrazolo [3, 4-d]-pyrimidin-6-one derivatives of potential antihypertensive activity
JPH04334368A (ja) 新規抗ビールス化合物
OGAWA et al. Synthesis and antihypertensive activities of new 1, 4-dihydropyridine derivatives containing a nitrooxy moiety at the 3-ester position
KR960009427B1 (ko) 1,4-디히드로피리딘 유도체, 그의 약학적 조성물 및 그 제조방법
US4021434A (en) Sodium β-[2,6-dimethyl-3,5-bis(ethoxycarbonyl)-4-(3-nitrophenyl)-1,4-dihydropyridine-1-yl]ethyl sulfate
AU656261B2 (en) New 3-aminochroman spiro compounds, processes for their preparation and pharmaceutical compositions containing them
US4782069A (en) 1,4-Dihydropiridines and their use as antithrombotic drugs
US4940708A (en) 4-arylsulfonyl-3,4-dihydro-2(1H)-quinoxalinone-1-alkanoic acids, esters, and salts
US4556739A (en) 3,4-Dialkoxy-2-alkylcarbonyl analino compounds
US4705786A (en) Novel oxadiazolyl-1,4-dihydropyridines useful as antihypertensive agents
EP0207674B1 (en) 1,4-dihydropyridine derivatives, their preparation and their pharmaceutical use
EP0063359B1 (en) 1,4-dihydropyridine derivatives and processes for preparing the same
US4579859A (en) Vasodilating trinitratoalkyl esters of 2-cyano-1,4-dihydropyridines
EP0093945A2 (en) 1,4-Dihydropyridine derivatives
US5364860A (en) Naphthyridine compounds which inhibit tyrosine kinase and their pharmaceutical compositions
US4963554A (en) 6,7-dimethoxy-1,2-dihydro-2-arylquinazoline-3-oxides
US4562256A (en) 1,6-Dialkyl-3-substituted-4-nitrophenyl-4,7-dihydropyrazolo[3,4-b]pyridine-5-carboxylic acid esters
NL8004002A (nl) Chinolinederivaten en farmaceutische preparaten die een dergelijke verbinding bevatten, alsmede werkwijze voor het bereiden van deze verbindingen.
EP0285267A3 (en) Pyridine derivatives for treatment and prevention of liver damage, and their preparation

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 7908367-1

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 7908367-1

Format of ref document f/p: F